{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T18:37:05Z","timestamp":1761676625833},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,9]]},"abstract":"<jats:p>The first approved tissue-selective estrogen complex is a pairing of conjugated estrogen combined with the selective estrogen-receptor modulator, bazedoxifene. Advantages include relief of menopausal symptoms without the increased chance of bleeding or breast tenderness unlike with traditional estrogen-progestin therapy, which is associated with both bleeding and breast tenderness. Tissue-selective estrogen complex effects on relief of vasomotor symptoms, prevention of bone loss, improvement in vaginal symptoms, lack of significant cardiovascular effects beyond the expected 2-fold increase in venous thrombosis, neutral effect on breast, and protective effects on the endometrium are discussed.<\/jats:p>","DOI":"10.1097\/grf.0000000000000386","type":"journal-article","created":{"date-parts":[[2018,5,26]],"date-time":"2018-05-26T13:20:53Z","timestamp":1527340853000},"page":"463-469","source":"Crossref","is-referenced-by-count":7,"title":["Tissue-selective Estrogen Complex for Menopausal Hormone Therapy"],"prefix":"10.1097","volume":"61","author":[{"given":"JOANN V.","family":"PINKERTON","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230911","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1080\/cmt.6.3.248.256","article-title":"Effect of raloxifene on sexual function in postmenopausal women","volume":"6","author":"Kessel","year":"2003","journal-title":"Climacteric"},{"key":"R2-20230911","first-page":"45","article-title":"Effect of raloxifene on the efficacy of an estradiol-releasing ring for treating vaginal atrophy in postmenopausal women","volume":"10","author":"Pinkerton","year":"2003","journal-title":"Menopause"},{"issue":"pt 1","key":"R3-20230911","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1097\/GME.0b013e318031a83d","article-title":"The effects of combined raloxifene and oral estrogen on vasomotor symptoms and endometrial safety","volume":"14","author":"Stovall","year":"2007","journal-title":"Menopause"},{"key":"R4-20230911","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1097\/gme.0b013e31823dbbca","article-title":"Using bazedoxifene plus conjugated estrogens for treating postmenopausal women: a comprehensive review","volume":"19","author":"Taylor","year":"2012","journal-title":"Menopause"},{"key":"R5-20230911","doi-asserted-by":"crossref","first-page":"e8659","DOI":"10.1097\/MD.0000000000008659","article-title":"Efficacy and safety of bazedoxifene in postmenopausal women with osteoporosis: a systematic review and meta-analysis","volume":"96","author":"Peng","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"R6-20230911","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.maturitas.2013.06.008","article-title":"Assessment of the safety of long-term bazedoxifene treatment on the reproductive tract in postmenopausal women with osteoporosis: results of a 7-year, randomized, placebo-controlled, phase 3 study","volume":"76","author":"Palacios","year":"2013","journal-title":"Maturitas"},{"key":"R7-20230911","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1002\/jcp.24324","article-title":"Evolution of the tissue selective estrogen complex (TSEC)","volume":"228","author":"Komm","year":"2013","journal-title":"J Cell Physiol"},{"key":"R8-20230911","doi-asserted-by":"crossref","first-page":"5706","DOI":"10.1210\/en.2012-1583","article-title":"Effects of the conjugated equine estrogen\/bazedoxifene tissue-selective estrogen complex (TSEC) on mammary gland and breast cancer in mice","volume":"153","author":"Song","year":"2012","journal-title":"Endocrinology"},{"key":"R9-20230911","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1097\/GME.0b013e318271f5e7","article-title":"Breast density changes in a randomized controlled trial evaluating bazedoxifene\/conjugated estrogens","volume":"20","author":"Harvey","year":"2013","journal-title":"Menopause"},{"key":"R10-20230911","first-page":"465","article-title":"Management of osteoporosis and menopausal symptoms: focus on bazedoxifene\/conjugated estrogen combination","volume":"5","author":"Mirkin","year":"2013","journal-title":"Int J Womens Health"},{"key":"R11-20230911","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.fertnstert.2009.02.093","article-title":"Efficacy of tissue-selective estrogen complex (TSEC) of bazedoxifene\/conjugated estrogens (BZA\/CE) for osteoporosis prevention in at-risk postmenopausal women","volume":"92","author":"Lindsay","year":"2009","journal-title":"Fertil Steril"},{"key":"R12-20230911","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.288.3.321","article-title":"Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women\u2019s Health Initiative randomized controlled trial","volume":"288","author":"Rossouw","year":"2002","journal-title":"JAMA"},{"key":"R13-20230911","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/j.fertnstert.2009.05.094","article-title":"Endometrial effects of a tissue selective estrogen complex (TSEC) containing bazedoxifene\/conjugated estrogens as a menopausal therapy","volume":"92","author":"Pickar","year":"2009","journal-title":"Fertil Steril"},{"key":"R14-20230911","first-page":"1","article-title":"Differential effects of menopausal therapies on the endometrium","volume":"21","author":"Mirkin","year":"2014","journal-title":"Menopause"},{"key":"R15-20230911","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.fertnstert.2009.03.113","article-title":"Evaluation of bazedoxifene\/ conjugated estrogens for the treatment of menopausal symptoms and effects on metabolic parameters and overall safety profile","volume":"92","author":"Lobo","year":"2009","journal-title":"Fertil Steril"},{"key":"R16-20230911","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1097\/gme.0b013e3181a7df0d","article-title":"Relief of vasomotor symptoms with the tissue-selective estrogen complex containing bazedoxifene\/conjugated estrogens: a randomized, controlled trial","volume":"16","author":"Pinkerton","year":"2009","journal-title":"Menopause"},{"key":"R17-20230911","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.maturitas.2016.09.010","article-title":"Direct and indirect effects of conjugated estrogens\/bazedoxifene treatment on quality of life in postmenopausal women","volume":"94","author":"Abraham","year":"2016","journal-title":"Maturitas"},{"key":"R18-20230911","doi-asserted-by":"crossref","first-page":"E189","DOI":"10.1210\/jc.2013-1707","article-title":"SMART-5 Investigators. Effects of bazedoxifene\/conjugated estrogens on the endometrium and bone: a randomized trial","volume":"99","author":"Pinkerton","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"key":"R19-20230911","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1097\/gme.0b013e3181b7c65f","article-title":"A randomized, placebo- and active-controlled trial of bazedoxifene\/conjugated estrogens for treatment of moderate to severe vulvar\/vaginal atrophy in postmenopausal women","volume":"17","author":"Kagan","year":"2010","journal-title":"Menopause"},{"key":"R20-20230911","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.maturitas.2017.03.315","article-title":"Relationship between changes in vulvar-vaginal atrophy and changes in sexual functioning","volume":"100","author":"Pinkerton","year":"2017","journal-title":"Maturitas"},{"key":"R21-20230911","first-page":"1221","article-title":"Breast parameters with bazedoxifene\/conjugated estrogens in randomized, controlled trials of postmenopausal women","volume":"17","author":"Pinkerton","year":"2010","journal-title":"Menopause"},{"key":"R22-20230911","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1097\/AOG.0b013e31828c5974","article-title":"Breast effects of bazedoxifene-conjugated estrogens: a randomized controlled trial","volume":"121","author":"Pinkerton","year":"2013","journal-title":"Obstet Gynecol"},{"key":"R23-20230911","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/j.fertnstert.2009.05.093","article-title":"Bazedoxifene\/conjugated estrogens (BZA\/CE): incidence of uterine bleeding in postmenopausal women","volume":"92","author":"Archer","year":"2009","journal-title":"Fertil Steril"},{"key":"R24-20230911","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1097\/GME.0000000000000541","article-title":"The effect of conjugated estrogens\/bazedoxifene therapy on body weight of postmenopausal women: pooled analysis of five randomized, placebo-controlled trials","volume":"23","author":"Black","year":"2016","journal-title":"Menopause"}],"container-title":["Clinical Obstetrics &amp; Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00003081-201809000-00007","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,11]],"date-time":"2023-09-11T08:14:43Z","timestamp":1694420083000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00003081-201809000-00007"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9]]},"references-count":24,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/grf.0000000000000386","relation":{},"ISSN":["0009-9201"],"issn-type":[{"value":"0009-9201","type":"print"}],"subject":[],"published":{"date-parts":[[2018,9]]}}}